Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : Á¦Ç° À¯Çüº°, ¸µÄ¿ À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°
Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography
»óǰÄÚµå : 1358031
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,151,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,569,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,671,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀåÀº 2023³â¿¡´Â 53¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2030³â¿¡´Â 136¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2030³â) CAGRÀº 14.2%ÀÔ´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 53¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ CAGR 14.20% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 136¾ï 5,000¸¸ ´Þ·¯
¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå Á¡À¯À²(%), Á¦Ç° À¯Çüº°, 2023³â
Antibody Drug Conjugates Market-IMG1

Ç×ü¾à¹°Á¢ÇÕü(ADC)´Â ÀϹÝÀûÀ¸·Î È­ÇÐÀû ¸µÄ¿¸¦ ÅëÇØ ¼¼Æ÷ µ¶¼º ¾à¹°°ú °øÀ¯ °áÇÕµÈ ´ÜÀÏ Å¬·Ð Ç×ü(mAb)´Ù. ADC´Â ¾Ï¼¼Æ÷¸¦ Á¤È®Çϰí È¿À²ÀûÀ¸·Î Á¦°ÅÇϱâ À§ÇØ Ã·´Ü ƯÀÌÀû Ç¥ÀûÈ­ ´É·Â°ú °­·ÂÇÑ »ì»ó È¿°úÀÇ ÀåÁ¡À» °áÇÕÇÏ¿© Ç×¾ÏÁ¦ 2000³â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ ÃÖÃÊÀÇ ADCÀÎ ÆÄµµ¼¼ºê(ÁªÅõÁÖ¸¿-¿ÀÁ¶°¡¸¶À̽Å)¸¦ ½ÂÀÎÇÑ ÀÌÈÄ ÇöÀç±îÁö ¼¼°è¿¡¼­ 14°³ÀÇ ADC°¡ ½ÃÆÇ Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ ÇöÀç 100°³ ÀÌ»óÀÇ ADC Èĺ¸¹°ÁúÀÌ ÀÓ»ó´Ü°è¿¡¼­ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. Ç×ü¾à¹°Á¢ÇÕü(ADC)´Â »ýºÐÇØ °¡´ÉÇÑ ¾ÈÁ¤µÈ ¸µÄ¿¸¦ ÅëÇØ ´ÜŬ·Ð Ç×ü¿¡ ¸Å¿ì °­·ÂÇÑ ¼¼Æ÷µ¶¼º Ç×¾ÏÁ¦¸¦ °áÇÕÇÏ¿© ¾Ï°ú Á¤»ó Á¶Á÷À» ½Äº°ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸µÄ¿´Â Àý´Ü °¡´ÉÇÑ ¸µÄ¿¿Í Àý´Ü ºÒ°¡´ÉÇÑ ¸µÄ¿°¡ ÀÖ½À´Ï´Ù. ¸µÄ¿ ±â¼úÀÇ ¹ßÀüÀº ´ÜÀÏ Å¬·Ð Ç×ü¸¦ ¼¼Æ÷ µ¶¼º Ç×¾ÏÁ¦¿¡ °áÇÕÇÏ¿© ¾à¹°ÀÇ ¾àµ¿ÇÐÀ» Á¦¾îÇÏ°í ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ¼¼Æ÷ µ¶¼º ¾à¹°ÀÇ Àü´ÞÀ» Å©°Ô Çâ»ó½ÃŰ´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Ç¥Àû Ç×ü¾à¹°Á¢ÇÕü¸¦ ƯÁ¤ Á¾¾ç Ç׿ø¿¡ ƯÀÌÀûÀ¸·Î °áÇÕ½Ã۰í, Ç׿ø-Ç×ü º¹ÇÕü¸¦ ³»ÀçÈ­ÇÏ¿© °áÇÕµÈ ¼¼Æ÷µ¶¼º ¾à¹°À» Á¾¾ç ¼¼Æ÷ ³»·Î ÁýÁßÀûÀ¸·Î Àü´ÞÇÏ´Â °ÍÀÌ Ç×ü Ç¥Àû È­Çпä¹ýÀÇ È¿°ú¿¡ Áß¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¾Ï Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ADC Èĺ¸¹°ÁúÀÇ ½ÂÀÎÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Á¦¾àȸ»ç ±æ¸®¾îµå »çÀ̾𽺴 2023³â 2¿ù 3ÀÏ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ È£¸£¸ó ¼ö¿ëü(HR) ¾ç¼º, Àΰ£ »óÇǼ¼Æ÷ ¼ºÀåÀÎÀÚ ¼ö¿ëü 2(HER2) À½¼ºÀÎ ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º À¯¹æ¾Ï(IHC 0, IHC 1 ¶Ç´Â IHC 2/ISH-) ¼ºÀΠȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇÑ Æ®·Îµ¨ºñ(sacituzumab govitecan-hziy)ÀÇ ½ÂÀÎÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ È¯ÀÚµéÀº ³»ºÐºñ ¿ä¹ýÀ» ¹ÞÀº ÀûÀÌ ÀÖ°í, ÀüÀÌ ´Ü°è¿¡¼­ ÃÖ¼Ò 2ȸ ÀÌ»óÀÇ Àü½Å ¿ä¹ýÀ» Ãß°¡·Î ¹ÞÀº ÀûÀÌ ÀÖ¾î¾ß ÇÕ´Ï´Ù.

º» ½ÃÇèÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå - ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : Á¦Ç° À¯Çüº°, 2018-2030³â

Á¦6Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : ¸µÄ¿ À¯Çüº°, 2018-2030³â

Á¦7Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : ¿ëµµº°, 2018-2030³â

Á¦8Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : À¯Åë ä³Îº°, 2018-2030³â

Á¦9Àå ¼¼°èÀÇ Ç×ü¾à¹°Á¢ÇÕü(ADC) ½ÃÀå : Áö¿ªº°, 2018-2030³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¼½¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global antibody drug conjugates market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to reach US$ 13.65 billion by 2030, exhibiting a CAGR of 14.2% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 5.38 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 14.20% 2030 Value Projection: US$ 13.65 Bn
Global Antibody Drug Conjugates Market Share (%), By Product Type, 2023
Antibody Drug Conjugates Market - IMG1

Antibody Drug Conjugate (ADC) is typically made up of a monoclonal antibody (mAb) covalently attached to a cytotoxic drug via a chemical linker. It combines the advantages of highly specific targeting ability and a highly potent killing effect to achieve accurate and efficient elimination of cancer cells, making it one of the hotspots for anticancer drug research and development. Since the approval of the first ADC, Padcev (gemtuzumab ozogamicin) in 2000 by the U.S. Food and Drug Administration (FDA), till now 14 ADCs have been approved for market use worldwide. Furthermore, over 100 ADC candidates are currently being studied in clinical stages. Antibody-drug conjugates attach highly potent cytotoxic anticancer agents to monoclonal antibodies via biodegradable, stable linkers and discriminate between cancer and normal tissue. These linkers are either cleavable or non-cleavable. Linker technology advancements are required to attach monoclonal antibodies to cytotoxic anticancer agents, allowing control over drug pharmacokinetics and significantly improving cytotoxic agent delivery to cancer cells. The specific binding of the targeting antibody-drug conjugate to the specific tumor antigen and the internalization of the antigen-antibody complex to ensure focused delivery of the conjugated cytotoxic agent inside tumor cells are critical to the efficacy of antibody-targeted chemotherapy.

Market Dynamics

Approvals of novel ADC candidates for the treatment of cancer are anticipated to support the market growth over the forecasted period. For instance, on February 3, 2023, Gilead Sciences, Inc., a pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for Trodelvy (sacituzumab govitecan-hziy) to be used in treating adult patients afflicted with inoperable locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-). These patients should have previously undergone endocrine-based therapy and received a minimum of two additional systemic therapies in the metastatic phase.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Antibody Drug Conjugates Market - COVID-19 Impact Analysis

5. Global Antibody Drug Conjugates Market, By Product Type, 2018 - 2030, (US$ Bn)

6. Global Antibody Drug Conjugates Market, By Linker Type, 2018 - 2030, (US$ Bn)

7. Global Antibody Drug Conjugates Market, By Application, 2018 - 2030, (US$ Bn)

8. Global Antibody Drug Conjugates Market, By Distribution Channel , 2018 - 2030, (US$ Bn)

9. Global Antibody Drug Conjugates Market, By Region, 2018 - 2030, (US$ Bn)

10. Competitive Landscape

11. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â